Blood pressure management and renal protection: Revisiting hypertensive nephropathy

被引:8
作者
Kao, Ting-Wei [1 ]
Huang, Chin-Chou [2 ,3 ,4 ,5 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan
[3] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
[4] Natl Yang Ming Chiao Tung Univ, Cardiovasc Res Ctr, Taipei, Taiwan
[5] Natl Yang Ming Chiao Tung Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan
关键词
Antihypertensive agents; Blood pressure; Hypertensive nephropathy; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; HEART-FAILURE; RISK; PROGRESSION; DYSFUNCTION; OUTCOMES; DECLINE; METAANALYSIS; MORTALITY;
D O I
10.1097/JCMA.0000000000000600
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertension has traditionally been the most common cardiovascular disease, and epidemiological studies suggest that the incidence continues to rise. Despite a plethora of antihypertensive agents, the management of blood pressure (BP) remains suboptimal. Addressing this issue is paramount to minimize hypertensive complications, including hypertensive nephropathy, a clinical entity whose definition has been challenged recently. Still, accumulating studies endorse poorly managed BP as an independent risk factor for both the onset of renal dysfunction and aggravation of baseline kidney disease. Nevertheless, current recommendations are not only discordant from one another but also offer inadequate evidence for the optimal BP control targets for renal protection, as since the cutoff values were primarily established on the premise of minimizing cardiovascular sequelae rather than kidney dysfunction. Although intense BP management was traditionally considered to compromise perfusion toward renal parenchyma, literature has gradually established that renal prognosis is more favorable as compared with the standard threshold. This review aims to elucidate the renal impact of poorly controlled hypertension, elaborate on contemporary clinical references for BP control, and propose future directions to improve the holistic care of hypertensive individuals.
引用
收藏
页码:911 / 916
页数:6
相关论文
共 55 条
  • [1] The Leading Causes of Death in the US for 2020
    Ahmad, Farida B.
    Anderson, Robert N.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (18): : 1829 - 1830
  • [2] Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease
    Angeli, Fabio
    Gentile, Giorgio
    Trapasso, Monica
    Verdecchia, Paolo
    Reboldi, Gianpaolo
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2018, 32 (8-9) : 625 - 632
  • [4] Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
    Appel, Lawrence J.
    Wright, Jackson T., Jr.
    Greene, Tom
    Agodoa, Lawrence Y.
    Astor, Brad C.
    Bakris, George L.
    Cleveland, William H.
    Charleston, Jeanne
    Contreras, Gabriel
    Faulkner, Marquetta L.
    Gabbai, Francis B.
    Gassman, Jennifer J.
    Hebert, Lee A.
    Jamerson, Kenneth A.
    Kopple, Joel D.
    Kusek, John W.
    Lash, James P.
    Lea, Janice P.
    Lewis, Julia B.
    Lipkowitz, Michael S.
    Massry, Shaul G.
    Miller, Edgar R.
    Norris, Keith
    Phillips, Robert A.
    Pogue, Velvie A.
    Randall, Otelio S.
    Rostand, Stephen G.
    Smogorzewski, Miroslaw J.
    Toto, Robert D.
    Wang, Xuelei
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) : 918 - 929
  • [5] ACC/AHA Versus ESC/ESH on Hypertension Guidelines
    Bakris, George
    Ali, Waleed
    Parati, Gianfranco
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (23) : 3018 - 3026
  • [6] The predictive value of 2-MG and TGF- for elderly hypertensive nephropathy
    Cao, Junjie
    Hou, Rui
    Lu, Jingqian
    Zhang, Kongyan
    Zhao, Cui
    Jiang, Haisen
    Feng, Yumei
    Wang, Yiwei
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (04) : 3065 - 3070
  • [7] Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology
    Carriazo, Sol
    Vanessa Perez-Gomez, Maria
    Ortiz, Alberto
    [J]. CLINICAL KIDNEY JOURNAL, 2020, 13 (04) : 504 - 509
  • [8] Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines
    Chang, Alex R.
    Loser, Meghan
    Malhotra, Rakesh
    Appel, Lawrence J.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 14 (01): : 161 - 169
  • [9] APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD
    Chen, Teresa K.
    Tin, Adrienne
    Peralta, Carmen A.
    Appel, Lawrence J.
    Choi, Michael J.
    Lipkowitz, Michael S.
    Winkler, Cheryl A.
    Estrella, Michelle M.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (11): : 1771 - 1777
  • [10] Effects of Intensive BP Control in CKD
    Cheung, Alfred K.
    Rahman, Mahboob
    Reboussin, David M.
    Craven, Timothy E.
    Greene, Tom
    Kimmel, Paul L.
    Cushman, William C.
    Hawfield, Amret T.
    Johnson, Karen C.
    Lewis, Cora E.
    Oparil, Suzanne
    Rocco, Michael V.
    Sink, Kaycee M.
    Whelton, Paul K.
    Wright, Jackson T., Jr.
    Basile, Jan
    Beddhu, Srinivasan
    Bhatt, Udayan
    Chang, Tara I.
    Chertow, Glenn M.
    Chonchol, Michel
    Freedman, Barry I.
    Haley, William
    Ix, Joachim H.
    Katz, Lois A.
    Killeen, Anthony A.
    Papademetriou, Vasilios
    Ricardo, Ana C.
    Servilla, Karen
    Wall, Barry
    Wolfgram, Dawn
    Yee, Jerry
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (09): : 2812 - 2823